Frost & Sullivan Presents 2005 Product Innovation Award to Bruker Daltonics.BILLERICA, Mass. -- Bruker Daltonics Inc. today announced its selection for the Frost & Sullivan 2005 Product Innovation Award. This award is in recognition of Bruker Daltonics' contributions to a broad array of mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. technologies and for its commitment to the growing field of proteomics. "Bruker Daltonics has been highly proactive in leveraging its array of mass spectrometry technologies towards drug discovery and clinical research applications. The key competitive and differentiating factor that provides Bruker Daltonics the leading edge is its ability to enhance technology. This is done in tandem with realizing meaningful life sciences applications through an integrated system solutions approach from the sample preparation phase to the data integration stage in protein identification," said Frost & Sullivan Healthcare Analyst Charanya Ramachandran. "The expansion of Bruker Daltonics' ClinProt product portfolio has shown a tremendous promise to move biomarker discovery and future molecular diagnostics to the next dimension. Bruker Daltonics has streamlined the proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. workflow with the introduction of bioinformatics tools that will complement the use of ClinProt for effective data analysis," stated Frost & Sullivan Sumit Sharma, Director, Healthcare Research. "In recognition of this technology giant's core competencies in research and development," Frost & Sullivan President Krishna Srinivasan said he "applauds Bruker Daltonics for its persistent efforts in bringing out a multifaceted product line to further bioresearch bi·o·re·search n. Research in the biological sciences. and meet customer needs by offering an integrated solution." Given that Bruker Daltonics continues to exhibit an outstanding dedication to life sciences research, both in-house and through alliances, Frost & Sullivan expects Bruker Daltonics to retain its leading position in mass spectrometry and accelerate proteome research in the future. Frank Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker Daltonics, commented: "We are quite gratified grat·i·fy tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies 1. To please or satisfy: His achievement gratified his father. See Synonyms at please. 2. by this award, and indeed pleased to have been recognized by Frost & Sullivan for the fifth time now in four years for our innovation and growth strategy in the life sciences." ABOUT BRUKER BIOSCIENCES (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ) Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. , please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion